| Deal value | $250M |
|---|---|
| Share of market cap | 10.1% |
Key highlights
- Gross proceeds of approximately $250 million from accredited investors in a PIPE transaction
- Sale of 11,340,000 American depositary shares (ADSs) at $22.04 per share
- Closing of the private placement scheduled for October 27, 2026
- Registration statement for the resale of ADSs to be filed within 15 days of closing
- Capital earmarked for pipeline asset development and working capital requirements
What Is the Capital Raise?
Zai Lab Limited has executed a securities purchase agreement with a group of accredited investors for a private placement of 11,340,000 American depositary shares. Each ADS represents ten ordinary shares of the company, priced at $22.04 per unit. The transaction is structured as a Private Investment in Public Equity (PIPE), which typically allows for efficient capital entry with institutional backing. The closing is expected to occur on or about October 27, 2026, contingent upon standard closing conditions. Following the transaction, Zai Lab has committed to filing a resale registration statement with the SEC to provide liquidity for the newly issued securities.
Use of Proceeds
- Advancement of the clinical development pipeline for oncology and immunology assets
- Funding of ongoing and future research and development activities
- Enhancement of working capital to support operational scaling
- General corporate purposes to maintain financial flexibility through 2027
- Strategic support for commercial-stage product stabilization and growth
Financial Context
This $250 million raise follows a pattern of strategic financing for Zai Lab, which previously completed a $200 million underwritten public offering in late 2024. Throughout 2025 and early 2026, the company also established multiple revolving credit facilities with several major banks, totaling over $190 million in available liquidity. This latest infusion of capital arrives just ahead of the company's scheduled third-quarter 2026 financial results on November 5. Management previously projected that operating expenses would remain stable through the end of 2026, with a return to meaningful commercial growth anticipated in the 2027 fiscal year.
Up 6.5% since our story on 23 Oct: $22.04 when we broke it → $23.47 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $24.06 |
|---|---|
| 20 Oct | $25.08 |
| 21 Oct | $24.20 |
| 22 Oct | $22.04 |
| 23 Oct | $24.03 |
| 26 Oct | $24.34 |
| 27 Oct | $23.58 |
| 28 Oct | $23.04 |
| 29 Oct | $22.36 |
| 30 Oct | $22.07 |
| 2 Nov | $21.66 |
| 3 Nov | $21.96 |
| 4 Nov | $22.80 |
| 5 Nov | $22.60 |
| 6 Nov | $25.48 |
| 9 Nov | $26.86 |
| 10 Nov | $26.43 |
| 11 Nov | $26.42 |
| 12 Nov | $26.04 |
| 13 Nov | $24.60 |
| 16 Nov | $23.47 |
Business Overview
Zai Lab Limited is a commercial-stage biopharmaceutical company focused on bringing transformative medicines to patients in China and globally. The firm specializes in the therapeutic areas of oncology, immunology, and infectious diseases, maintaining operations in both Shanghai and Cambridge, Massachusetts. As an automated intelligence platform notes, the company operates without a traditional order backlog due to the nature of its pharmaceutical sales. Current market technicals show an RSI of 38.1, following a monthly price change of negative 16.55 percent, as the company prepares to transition several key pipeline assets into later-stage clinical milestones.
| Date | Announcement | Amount |
|---|---|---|
| 22 Oct 2026 | Private placement (PIPE) of 11,340,000 American Depositary SharesSource: businesswire.com | $250.0 Million |
| 25 Feb 2026 | Working capital revolving credit facility agreement with Bank of CommunicationsSource: SEC filing | $41.1 Million |
| 16 Oct 2025 | Revolving line of credit contract with Industrial BankSource: SEC filing | $42.1 Million |
| 06 Aug 2025 | Working capital credit agreement with China Merchants BankSource: SEC filing | $69.6 Million |
| 03 Jan 2025 | Revolving working capital loan facility agreement with Bank of CommunicationsSource: SEC filing | $41.1 Million |
| 14 Nov 2024 | Underwritten public offering of 7,843,137 American Depositary SharesSource: ir.zailaboratory.com | $200.0 Million |
| Share price | $22.04 |
|---|---|
| Market cap | $2.5B |
| Revenue (annual) | $460M |
| 1-month price change | -16.55% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Zai Lab Limited announcing a $250 million private placement of American depositary shares.
Track Zai Lab Ltd live
Get the next Zai Lab Ltd SEC filing seconds after it lands.



